# 参考文献

## 第一章

[1]INGALLS A M, DICKIE M M, SNELL G D.Obese, a new mutation in the house mouse[J].Journal of Heredity，1950，41（12）：317-318.

[2]HUMMEL K P, DICKIE M M, COLEMAN D L.Diabetes, a new mutaton in the mouse[J].Science，1966，153（3740）：1127-1128.

[3]COLEMAN D L, HUMMEL K P.Effects of parabiosis of normal with genetically diabetic mice[J].American Journal of Physiology，1969，217（5）：1298-1304.

[4]COLEMAN D L.Effects of parabiosis of obese with diabetes and normal mice[J].Diabetologia，1973，9（4）：294-298.

[5]BAHARY N, LEIBEL R L, JOSEPH L, et al.Molecular mapping of the mouse db mutation[J].Proceedings of the National Academy of Sciences of the United States of America，1990，87（21）：8642-8646.

[6]BAHARY N, ZORICH G，PACHTER JE, et al.Molecular genetic linkage maps of mouse chromosomes 4 and 6[J].Genomics，1991，11（1）：33-47.

[7]FRIEDMAN J M, LEIBEL R L, SIEGEL D S, et al.Molecular mapping of the mouse ob mutation[J].Genomics，1991，11（4）：1054-1062.

[8]ZHANG Y, et al.Positional cloning of the mouse obese gene and its human homologue[J].Nature，1994，372（6505）：425-432.

[9]TARTAGLIA L A, et al.Identification and expression cloning of a leptin receptor, OB-R[J].Cell，1995，83（7）：1263-1271.

[10]FRIEDMAN J M, HALAAS J L.Leptin and the regulation of body weight in mammals[J].Nature，1998，395（6704）：763-770.

[11]COLEMAN D L.A historical perspective on leptin[J].Nature，2010，Medicine 16（10）：1097-1099.[12]LOFFREDO FRANCESCO S, et al.Growth differentiation factor 11 is a circulating factor that reverses age-related cardiac hypertrophy[J].Cell，2013，153（4）：828-839.

[13]FRIEDMAN J.20 YEARS OF LEPTIN：Leptin at 20：an overview[J].Journal of Endocrinology，2014，223（1）：T1-T8.

[14]KATSIMPARDI L, et al.Vascular and neurogenic rejuvenation of the aging mouse brain by young systemic factors[J].Science，2014，344（6184）：630-634.

[15]LAVIANO A.Young blood[J].New England Journal of Medicine，2014，371（6）：573-575.

[16]KAISER J.‘Rejuvenating'protein doubted[J].Science，2015，348（6237）：849-849.

## 第二章

[17]COHEN S N, CHANG A C Y, BOYER H W, et al.Construction of biologically functional bacterial plasmids in vitro[J].Proceedings of the National Academy of Sciences of the United States of America，1973，70（11）：3240-3244.

[18]HOGAN S, et al.Studies on the antiobesity activity of tetrahydrolipstatin, a potent and selective inhibitor of pancreatic lipase[J].International Journal of Obesity，1987，11（Suppl 3）：35-42.

[19]WEINTRAUB M.Long-term weight control study：conclusions[J].Clinical Pharmacology&Therapeutics，1992，51（5）：642-646.

[20]BRAY G A.Amphetamine：thejanus of treatment for obesity[J].Obesity Research，1994，2（3）：282-285.

[21]CAMPFIELD L A, SMITH F J, GUISEZ Y, et al.Recombinant mouse OB protein：evidence for a peripheral signal linking adiposity and central neural networks[J].Science，1995，269（5223）：546-549.

[22]HALAAS J L, et al.Weight-reducing effects of the plasma protein encoded by the obese gene[J].Science，1995，269（5223）：543-546.

[23]PELLEYMOUNTER M A, et al.Effects of the obese gene product on body weight regulation in ob/ob mice[J].Science，1995，269（5223）：540-543.

[24]STEPHENS T W, et al.The role of neuropeptide Y in the antiobesity action of the obese gene product[J].Nature，1995，377（6549）：530-532.

[25]MONTAGUE C T, e t a l.Congenital leptin deficiency is associated with severe early-onset obesity in humans[J].Nature，1997，387（6636）：903-908.

[26]FAROOQI I S, et al.Beneficial effects of leptin on obesity, T cellhyporesponsiveness, and neuroend ocrine/metabolic dysfunction of human congenitalleptin deficiency[J].The Journal of Clinical Investigation，2002，110（8）：1093-1103.

[27]ORAL E A, et al.Leptin-replacement therapy for lipodystrophy[J].New England Journal of Medicine，2002，346（8）：570-578.

[28]VAN MARKEN LICHTENBELT W D, et al.Cold-activated brown adipose tissue in healthy men[J].New England Journal of Medicine，2009，360（15）：1500-1508.

[29]HILL J O, WYATT H R, PETERS J C.Energy balance and obesity[J].Circulation，2012，126（1）：126-132.

[30]COHEN S N.DNA cloning：a personal view after 40 years[J].Proceedings of the National Academy of Sciences，2013，110（39）：15521-15529.

[31]OGDEN C L, CARROLL M D, KIT B K, et al.Prevalence of childhood and adult obesity in the united states，2011-2012[J].JAMA，2014，311（8）：806-814.

[32]BURKE L K, HEISLER L K.5-hydroxytryptamine medications for the treatment of obesity[J].Journal of Neuroendocrinology，2015，27（6）：389-398.

[33]CYPESS AARON M, et al.Activation of human brown adiposetissue by aβ3-adrenergic receptor agonist[J].Cell Metabolism，2015，21（1）：33-38.

[34]KAHAN S, ZVENYACH T.Obesity as a disease：current policies and implications for the future[J].Current Obesity Reports，2016，5（2）：291-297.

## 第三章

[35]BLOCH K.The biological synthesis of cholesterol[J].Science，1965，150（3692）：19-28.

[36]BROWN M S, DANA S E, GOLDSTEIN J L.Regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in human fibroblasts by lipoproteins[J].Proceedings of the National Academy of Sciences，1973，70（7）：2162-2166.

[37]GOLDSTEIN J L, BROWN M S.Familial hypercholesterolemia：identification of a defect in the regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity associated with overproduction of cholesterol[J].Proceedings of the National Academy of Sciences，1973，70（10）：2804-2808.

[38]BROWN M S, GOLDSTEIN J L.Familial hypercholesterolemia：Defective binding of lipoproteins to cultured fibroblasts associated with impaired regulation of 3-hydroxy-3-methylglutaryl coenzyme a reductase activity[J].Proceedings of the National Academy of Sciences，1974，71（3）：788-792.

[39]ENDO A, KURODA M, TANZAWA K.Competitive inhibition of 3-hydroxy-3-methylglutaryl coenzyme a reductase by ML-236A and ML-236B fungal metabolites, having hypocholesterolemic activity[J].FEBS Letters，1976，72（2）：323-326.

[40]ENDO A, KURODA M, TSUJITA Y.ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinium[J].J Antibiot（Tokyo），1976，29（12）：1346-1348.

[41]GOLDSTEIN L J, BROWN S M.The low-density lipoprotein pathway and its relation to atherosclerosis[J].Annual Review of Biochemistry，1977，46（1）：897-930.

[42]BROWN M S, FAUST J R, GOLDSTEIN J L, et al.Induction of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity inhuman fibroblasts incubated with compactin（ML-236B），a competitive inhibitor of the reductase[J].Journal of Biological Chemistry，1978，253（4）：1121-1128.

[43]HOBBS H H, RUSSELL D W, BROWN M S, et al.The LDL receptor locus in familial hypercholesterolemia：mutational analysis of a membrane protein[J].Annual Review of Genetics，1990，24（1）：133-170.

[44]ABIFADEL M, et al.Mutations in PCSK9 cause autosomal dominant hyperchole sterolemia[J].Nature Genetics，2003，34（2）：154-156.

[45]MAXWELL K N, BRESLOW J L.Adenoviral-mediated expression of Pcsk 9 in mice results in a low-density lipoprotein receptor knockout phenotype[J].Proceedings of the National Academy of Sciences of the United States of America，2004，101（18）：7100-7105.

[46]COHEN J, et al.Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9[J].Nature Genetics，2005，37（2）：161-165.

[47]FOX K A, STEG P, EAGLE K A, et al.Decline in rates of death and heart failure in acute coronarysyndromes，1999-2006[J].JAMA，2007，297（17）：1892-1900.

[48]STOSSEL T P.The Discovery of Statins[J].Cell，2008，134（6）：903-905.

[49]SCHEKMAN R.Discovery of the cellular and molecular basis of cholesterol control[J].Proceedings of the National Academy of Sciences，2013，110（37）：14833-14836.

[50]AJUFO E, RADER D J.Recent advances in the pharmacological management of hypercholes-terolaemia[J].The Lancet Diabetes&Endocrinology，2016，4（5）：436-446.

## 第四章

[51]OPIE E L.Pathological changes affecting the islands of Langerhans of the pancreas[J].Journal of the Boston Society of Medical Sciences，1900，4（10）：251-260.

[52]SANGER F, TUPPY H.The amino-acid sequence in the pheny-lalanyl chain of insulin.1.The identi-fication of lower peptides from partial hydrolysates[J].Biochemical Journal，1951，49（4）：463-481.

[53]SANGER F, TUPPY H.The amino-acid sequence in thephenylalanyl chain of insulin.2.The investigation of peptides from enzymic hydrolysates[J].Biochemical Journal，1951，49（4）：481-490.

[54]SANGER F, THOMPSON E O P.The amino-acid sequence in the glycyl chain of insulin.1.The identification of lower peptides from partial hydrolysates[J].Biochemical Journal，1953，53（3）：353-366.

[55]SANGER F, THOMPSON E O P.The amino-acid sequence in the glycyl chain of insulin.2.The investigation of peptides from enzymic hydrolysates[J].Biochemical Journal，1953，53（3）：366-374.

[56]ROSENFELD L.Insulin：discovery and controversy[J].Clinical Chemistry，2002，48（12）：2270-2288.

[57]KATHRYN M K, GREG R.A history of diabetes：from antiquity to discovering insulin[J].British Journal of Nursing，2003，12（18）：1091-1095.

[58]BLISS M.Resurrections in Toronto：the emergence of insulin[J].Hormone Research in Paediatrics，2005，64（suppl 2）（Suppl.2）：98-102.[59]FENG J, et al.Discovery of alogliptin：a potent, selective，bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV[J].Journal of Medicinal Chemistry，2007，50（10）：2297-2300.

[60]HIMSWORTH H P.Diabetes mellitus：its differentiation into insulinsensitive and insulin-insensitive types[J].Diabetic Medicine，2011，28（12）：1440-1444.

[61]KARAMITSOS D T.The story of insulin discovery[J].Diabetes Research and Clinical Practice，2011，93：S2-S8.

[62]ROTH J, et al.Insulin's discovery：new insights on its ninetieth birthday[J].Diabetes/Metabolism Research and Reviews，2012，28（4）：293-304.

[63]HIMSWORTH H P.Diabetes Mellitus：its differentiation into insulin sensitive and insulin-insensitive types[J].International Journal of Epidemiology，2013，42（6）：1594-1598.

[64]TUOMI T, et al.The many faces of diabetes：a disease with increasing heterogeneity[J].The Lancet，2014，383（9922）：1084-1094.

[65]ZIMMET P Z, MAGLIANO D J, HERMAN W H, et al.Diabetes：a 21st century challenge[J].The Lancet Diabetes&Endocri nology，2014，2（1）：56-64.

[66]AGULNICK A D, et al.Insulin-producing endocrine cells differentiated in vitro from human embryonic stem cells function in macroencapsulation devices in vivo[J].Stem Cells Translational Medicine，2015，4（10）：1214-1222.

[67]KARAMANOU M, PROTO-GEROU A, TSOUCALAS G, et al.Milestones in the history of diabetes mellitus：the main contributors[J].World Journal of Diabetes，2016，7（1）：1-7.




